CRIS Current Research Information System

DE BENEDITTIS, CATERINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.249
EU - Europa 2.189
AS - Asia 1.056
AF - Africa 178
SA - Sud America 11
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 4
Totale 6.692
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.243
GB - Regno Unito 686
SE - Svezia 358
IT - Italia 357
CN - Cina 344
VN - Vietnam 291
DE - Germania 284
SG - Singapore 184
IN - India 152
IE - Irlanda 112
RU - Federazione Russa 84
FR - Francia 83
TG - Togo 80
EE - Estonia 58
ZA - Sudafrica 56
UA - Ucraina 42
JO - Giordania 41
BG - Bulgaria 37
CH - Svizzera 25
CI - Costa d'Avorio 21
NG - Nigeria 20
BE - Belgio 15
FI - Finlandia 15
PL - Polonia 10
IR - Iran 9
LB - Libano 7
BR - Brasile 6
CA - Canada 6
NL - Olanda 6
JP - Giappone 5
KR - Corea 5
AU - Australia 4
CZ - Repubblica Ceca 4
EU - Europa 4
GR - Grecia 4
HR - Croazia 4
TR - Turchia 4
UZ - Uzbekistan 4
CL - Cile 3
HK - Hong Kong 2
NO - Norvegia 2
QA - Qatar 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BD - Bangladesh 1
BO - Bolivia 1
CO - Colombia 1
EG - Egitto 1
IL - Israele 1
IQ - Iraq 1
PK - Pakistan 1
PT - Portogallo 1
RO - Romania 1
SA - Arabia Saudita 1
TW - Taiwan 1
Totale 6.692
Salva come PNG Salva come JPEG
Città #
Southend 648
Fairfield 431
Chandler 416
Ashburn 238
Houston 210
Dong Ket 195
Wilmington 194
Woodbridge 189
Seattle 187
Singapore 157
Princeton 152
Cambridge 139
Dublin 112
Ann Arbor 104
Bologna 93
Lomé 80
Nanjing 62
Westminster 62
Beijing 58
Padova 52
New York 43
Amman 41
Medford 40
Sofia 37
Redmond 33
Bremen 30
Berlin 28
San Diego 28
Turin 28
Jinan 27
Santa Clara 27
Shenyang 25
Changsha 24
Hebei 24
Saint Petersburg 24
Abidjan 21
Abeokuta 20
Bern 20
Jiaxing 20
Nanchang 20
Brussels 15
Florence 15
Helsinki 15
Milan 15
Norwalk 15
Boardman 14
Mountain View 14
Redwood City 14
Haikou 11
Tianjin 11
Olalla 10
Dearborn 9
Des Moines 8
Forlì 8
Kraków 7
Falls Church 6
Guangzhou 6
Zhengzhou 6
Bareggio 5
Fuzhou 5
Hangzhou 5
Los Angeles 5
Phoenix 5
Taizhou 5
Tappahannock 5
Bühl 4
Faenza 4
Hefei 4
Lanzhou 4
Ningbo 4
São Paulo 4
Andover 3
Chicago 3
Costa Mesa 3
Frankfurt am Main 3
Fremont 3
Gilze 3
Henderson 3
Kunming 3
London 3
Monza 3
Paris 3
Portland 3
Toronto 3
Ulan-ude 3
Wolverhampton 3
Zanjan 3
Bengaluru 2
Boydton 2
Caltagirone 2
Castelnuovo Rangone 2
Cernusco sul Naviglio 2
Cesena 2
Deventer 2
Doha 2
Ferrara 2
Francofonte 2
Hounslow 2
Huzhou 2
Kuban 2
Totale 4.671
Salva come PNG Salva come JPEG
Nome #
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 202
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 183
Calreticulin: Challenges Posed by the Intrinsically Disordered Nature of Calreticulin to the Study of Its Function 155
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 149
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 142
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients 132
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 130
Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing 127
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 126
Best practices in chronic myeloid leukemia monitoring and management 121
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 120
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 120
The Heterogeneity of Skewness in T2W-Based Radiomics Predicts the Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer 115
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 113
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis 110
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 109
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 108
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 108
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 105
Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients 103
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 103
Ultra-Deep Sequencing (UDS) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 103
Outcomes following percutaneous treatment of biliary stones 103
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 102
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 100
Bcr-Abl kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the 2nd-generation TKI era 100
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 97
Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies 97
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 96
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 96
A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis 95
High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors 94
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 94
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. 94
Ultradeep-Amplicon Pyrosequencing for Mutation Detection in the Kinase Domain of BCR-ABL Revealed Artificial Low-Level Variants That Need to Be Avoided for Relevant Mutational Data Interpretation 94
PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience 93
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: the Bologna experience 93
Radiomics of cholangiocarcinoma on pretreatment CT can identify patients who would best respond to radioembolisation 93
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 91
HIGH RATE OF COMPLETE HEMATOLOGICAL RESPONSE IN ELDERLY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS BY INNOVATIVE SEQUENTIAL USE OF NILOTINIB AND IMATINIB: A GIMEMA CLINICAL TRIAL LAL 1408 90
Classification performance for covid patient prognosis from automatic ai segmentation—a single-center study 89
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse 88
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 88
Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2nd-Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement 86
Resistance to second-line tyrosine kinase inhibitor treatment in imatinib-resistant Philadelphia-positive leukemia patients can be anticipated by ultra-deep sequencing of the BCR-ABL kinase domain using Roche 454 technology 86
Serum total tryptase level confirms itself as a more reliable marker of mast cells burden in mast cell leukaemia (aleukaemic variant) 85
The impact of sensitive KIT D816V detection on recognition of Indolent Systemic Mastocytosis 84
Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia 84
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies 84
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia 83
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement 83
Portal Hypertensive Biliopathy in Adult Patients: Findings and Interventional Radiologic Treatment--A Single-Center Experience 83
Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients 82
Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene 80
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients 80
Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor 79
Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage 79
Percutaneous abdomino-pelvic abscess drainage in complicated Crohn’s disease 77
Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis 76
Present and future of molecular monitoring in chronic myeloid leukaemia. 75
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 75
Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase 73
Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case 72
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 72
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 71
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 71
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: follow up of a single-center Italian compassionate use 70
Deep sequencing of the bcr-abl kinase domain reveals a high frequency of bcr-abl35-ins insertion/truncation mutation in chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia patients 64
Diagnostic Accuracy of North America Expert Consensus Statement on Reporting CT Findings in Patients Suspected of Having COVID-19 Infection: An Italian Single-Center Experience 61
You have accessClinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters 56
Percutaneous management of postoperative Bile leak after hepato-pancreato-biliary surgery: a multi-center experience 55
Totale 6.897
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.238
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.238
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.333 0 0 4 86 169 150 224 181 221 106 104 88
2020/2021984 172 51 21 19 22 55 29 35 123 59 46 352
2021/20221.360 122 27 73 94 131 79 16 108 73 83 304 250
2022/20231.579 165 245 70 215 117 116 55 100 295 29 120 52
2023/2024367 19 74 19 30 31 98 14 10 28 10 9 25
2024/2025284 64 218 2 0 0 0 0 0 0 0 0 0
Totale 6.897